MedTrace Logo

Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy

NCT02581228 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-09-27

No results posted yet for this study

Summary

This is a retrospective, open label study to establish and validate a prediction technology for advanced melanoma patients under the 1st, 2nd and later treatment lines, with the immunotherapeutic drugs Ipilimumab, Pembrolizumab \& Nivolumab, in order to predict response rate and disease progression

Conditions

Interventions

DEVICE

ML-PrediCare

Sponsors & Collaborators

  • Optimata Ltd.

    lead INDUSTRY

Principal Investigators

  • Marina Kleiman, PhD · Optimata Ltd.

  • Michal Lotem, MD · Hadassah Medical Organization

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-04-30
Completion
2018-11-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02581228 on ClinicalTrials.gov